Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells

20 Jun 2023

Abstract excerpt

TP 53-mutant acute myeloid leukemia (AML) remains the ultimate therapeutic challenge. Epichaperomes, formed in malignant cells, consist of heat shock protein 90 (HSP90) and associated proteins that support the maturation, activity, and stability of oncogenic kinases and transcription factors including mutant p53. High-throughput drug screening identified HSP90 inhibitors as top hits in isogenic TP53-wild-type...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Effects of Radiation Exposure
Share to Heat shock proteins research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37339579
DOI: 10.1182/blood.2022019047

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cellsPMID 37339579Read ↗

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read ↗

Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.Semantic proximity Read ↗

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasmsSemantic proximity Read ↗

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical DevelopmentsSemantic proximity Read ↗

Nontransplant treatment approaches for myeloid neoplasm with mutated TP53.Semantic proximity Read ↗

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialSemantic proximity Read ↗

The role of TP53 in acute myeloid leukemia: Challenges and opportunitiesSemantic proximity Read ↗

Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutationsSemantic proximity Read ↗

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity Read ↗

Evaluating targeted therapies in older patients with TP53-mutated AML.Semantic proximity Read ↗

Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms.Semantic proximity Read ↗

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.